The Medibank Private Ltd (ASX: MPL) share price has yet to recover lost ground from the COVID‐19 crisis, but that could change by next week.
The MPL share price is down by around 10% since the start of 2020 when the S&P/ASX 200 Index (Index:^AXJO) dipped 3.5%.
The private health insurer is at least holding up better than its rival. The NIB Holdings Limited (ASX: NHF) share price shed nearly a quarter of its value over the same period.
Medibank share price health could soon improve
But the Medibank share price might get a chance to play catch-up to the rest of the market as Morgan Stanley thinks it could rally by nearly 10% by Tuesday.
That’s when the Australian Prudential Regulation Authority (APRA) is expected to release its private health insurance (PHI) statistics for the September quarter.
How APRA’s data feeds into Medibank’s stock valuation
The data will not only show the change in people with PHI but also the benefits paid. The first will provide insight into Medibank’s revenue growth (or lack of), while the latter will lend insight into its profit margin.
“We believe membership growth direction and the number of episodes will drive market expectations on MPL’s future earnings,” said Morgan Stanley.
The deferment of elective surgeries due to the pandemic is a boon for PHI companies but a drag for hospital stocks like the Ramsay Health Care Limited Fully Paid Ord. Shrs (ASX: RHC) share price. This is well understood by the market.
3 possible outcomes for the MPL share price
But the revenue growth outlook for insurers is convoluted by the deferred increase in premiums as the industry moved to help its customers through the recession.
Morgan Stanley believes there is one of three possible outcomes on Tuesday. The data could show a more than 0.5% drop in PHI membership, a flat outcome with no more than a 0.5% change, or a more than 0.5% increase.
The broker rates the probability of the first outcome (contraction) at 10% and the second flat outcome at 20%.
Pumped and primed
Its base case is for memberships to increase, which would add 2% or more to Medibank’s earnings per share in FY21.
More significantly, if this comes to pass, the broker reckons the stock will shoot up to $3.10 on the news.
The MPL share price is trading at $2.85 ahead of the market close.
However, if the data points to a 0.5% or worse decline, the stock could tumble to $2.50. In the flat scenario, the stock will hover around $2.80.
But Morgan Stanley is an optimist. It’s recommending the Medibank share price as “overweight” (or “buy”) with a price target of $3.10.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
More reading
- Why the Dubber Corp (ASX:DUB) share price is surging today
- Why are ASX tech shares all over the place today?
- Here’s how ASX investors have reacted to a Biden win
- Why the Aristocrat (ASX:ALL) share price could jump next week
- The Hipages (ASX:HPG) share price jumped 16% after its IPO
Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Broker tipping a ~10% jump in the Medibank (ASX:MPL) share price by Tuesday appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/36wB0bQ
Leave a Reply